Skip to main content
Erschienen in: Journal of Neuro-Oncology 2/2014

01.04.2014 | Topic Review

End-of-life symptoms and care in patients with primary malignant brain tumors: a systematic literature review

verfasst von: Tobias Walbert, Muhib Khan

Erschienen in: Journal of Neuro-Oncology | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

The aim of this study was to review the literature on end-of-life symptoms and end-of-life care of adult patients with high-grade glioma (HGG). Despite aggressive treatment, the survival of HGG patients is limited. Symptom management is paramount to maintain maximum quality of life. The goal of this review is to identify the symptoms and the potential needs of brain tumor patients and their caretakers at the end of life. A systematic literature search in PubMed and Cochrane databases was performed for the years 1946 through August 6th, 2013. A total of 6,196 article citations were identified. Based on predefined criteria, 32 articles were retained for detailed examination. Of these 32 articles, only 7 focused on end-of-life symptoms and interventions. All 7 studies were retrospective and focused on inpatients (3), outpatients (2) or both (2). All but one study involved formal hospice. Drowsiness and loss of consciousness was the most common symptom (1–90 %). Poor communication (64 and 90 %), focal neurological deficits (3–62 %), seizures (3–56 %), dysphagia (7–85 %) and headaches (4–62 %) were also frequent. Only 4 studies reported on palliative interventions. Our systematic review shows that HGG patients in the end-of-life phase have a consistently high symptom burden especially during the last days of life. There is no prospective or conclusive literature describing end-of-life symptom management in HGG patients. Prospective research will be needed to further define symptoms and management in the end-of-life phase.
Literatur
1.
Zurück zum Zitat Chakrabarti I, Cockburn M, Cozen W, Wang YP, Preston-Martin S (2005) A population-based description of glioblastoma multiforme in Los Angeles County, 1974-1999. Cancer 104:2798–2806PubMedCrossRef Chakrabarti I, Cockburn M, Cozen W, Wang YP, Preston-Martin S (2005) A population-based description of glioblastoma multiforme in Los Angeles County, 1974-1999. Cancer 104:2798–2806PubMedCrossRef
2.
Zurück zum Zitat Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996PubMedCrossRef Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996PubMedCrossRef
4.
Zurück zum Zitat Prados MD, Seiferheld W, Sandler HM, Buckner JC, Phillips T, Schultz C, Urtasun R, Davis R, Gutin P, Cascino TL, Greenberg HS, Curran WJ Jr (2004) Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: final report of RTOG 9404. Int J Radiat Oncol Biol Phys 58:1147–1152PubMedCrossRef Prados MD, Seiferheld W, Sandler HM, Buckner JC, Phillips T, Schultz C, Urtasun R, Davis R, Gutin P, Cascino TL, Greenberg HS, Curran WJ Jr (2004) Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: final report of RTOG 9404. Int J Radiat Oncol Biol Phys 58:1147–1152PubMedCrossRef
5.
Zurück zum Zitat van den Bent MJ, Carpentier AF, Brandes AA, Sanson M, Taphoorn MJ, Bernsen HJ, Frenay M, Tijssen CC, Grisold W, Sipos L, Haaxma-Reiche H, Kros JM, van Kouwenhoven MC, Vecht CJ, Allgeier A, Lacombe D, Gorlia T (2006) Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 24:2715–2722PubMedCrossRef van den Bent MJ, Carpentier AF, Brandes AA, Sanson M, Taphoorn MJ, Bernsen HJ, Frenay M, Tijssen CC, Grisold W, Sipos L, Haaxma-Reiche H, Kros JM, van Kouwenhoven MC, Vecht CJ, Allgeier A, Lacombe D, Gorlia T (2006) Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 24:2715–2722PubMedCrossRef
6.
Zurück zum Zitat Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6:e1000097PubMedCentralPubMedCrossRef Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6:e1000097PubMedCentralPubMedCrossRef
7.
Zurück zum Zitat Moore G, Collins A, Brand C, Gold M, Lethborg C, Murphy M, Sundararajan V, Philip J (2013) Palliative and supportive care needs of patients with high-grade glioma and their carers: a systematic review of qualitative literature. Patient Educ Couns 91:141–153PubMedCrossRef Moore G, Collins A, Brand C, Gold M, Lethborg C, Murphy M, Sundararajan V, Philip J (2013) Palliative and supportive care needs of patients with high-grade glioma and their carers: a systematic review of qualitative literature. Patient Educ Couns 91:141–153PubMedCrossRef
8.
Zurück zum Zitat Krouwer HG, Pallagi JL, Graves NM (2000) Management of seizures in brain tumor patients at the end of life. J Palliat Med 3:465–475PubMedCrossRef Krouwer HG, Pallagi JL, Graves NM (2000) Management of seizures in brain tumor patients at the end of life. J Palliat Med 3:465–475PubMedCrossRef
9.
Zurück zum Zitat Lipsman N, Skanda A, Kimmelman J, Bernstein M (2007) The attitudes of brain cancer patients and their caregivers towards death and dying: a qualitative study. BMC Palliat Care 6:7PubMedCentralPubMedCrossRef Lipsman N, Skanda A, Kimmelman J, Bernstein M (2007) The attitudes of brain cancer patients and their caregivers towards death and dying: a qualitative study. BMC Palliat Care 6:7PubMedCentralPubMedCrossRef
10.
Zurück zum Zitat Sizoo EM, Braam L, Postma TJ, Pasman HRW, Heimans JJ, Klein M, Reijneveld JC, Taphoorn MJB (2010) Symptoms and problems in the end-of-life phase of high-grade glioma patients. Neuro Oncol 12:1162–1166PubMedCentralPubMedCrossRef Sizoo EM, Braam L, Postma TJ, Pasman HRW, Heimans JJ, Klein M, Reijneveld JC, Taphoorn MJB (2010) Symptoms and problems in the end-of-life phase of high-grade glioma patients. Neuro Oncol 12:1162–1166PubMedCentralPubMedCrossRef
11.
Zurück zum Zitat Pace A, Di Lorenzo C, Lorenzo CD, Guariglia L, Jandolo B, Carapella CM, Pompili A (2009) End of life issues in brain tumor patients. J Neuro oncol 91:39–43CrossRef Pace A, Di Lorenzo C, Lorenzo CD, Guariglia L, Jandolo B, Carapella CM, Pompili A (2009) End of life issues in brain tumor patients. J Neuro oncol 91:39–43CrossRef
12.
Zurück zum Zitat Pace A, Villani V, Di Lorenzo C, Guariglia L, Maschio M, Pompili A, Carapella CM (2013) Epilepsy in the end-of-life phase in patients with high-grade gliomas. J Neuro oncol 111:83–86CrossRef Pace A, Villani V, Di Lorenzo C, Guariglia L, Maschio M, Pompili A, Carapella CM (2013) Epilepsy in the end-of-life phase in patients with high-grade gliomas. J Neuro oncol 111:83–86CrossRef
13.
Zurück zum Zitat Oberndorfer S, Lindeck-Pozza E, Lahrmann H, Struhal W, Hitzenberger P, Grisold W (2008) The end-of-life hospital setting in patients with glioblastoma. J Palliat Med 11:26–30PubMedCrossRef Oberndorfer S, Lindeck-Pozza E, Lahrmann H, Struhal W, Hitzenberger P, Grisold W (2008) The end-of-life hospital setting in patients with glioblastoma. J Palliat Med 11:26–30PubMedCrossRef
14.
Zurück zum Zitat Arber A, Faithfull S, Plaskota M, Lucas C, de Vries K (2010) A study of patients with a primary malignant brain tumour and their carers: symptoms and access to services. Int J Palliat Nurs 16:24–30PubMed Arber A, Faithfull S, Plaskota M, Lucas C, de Vries K (2010) A study of patients with a primary malignant brain tumour and their carers: symptoms and access to services. Int J Palliat Nurs 16:24–30PubMed
15.
Zurück zum Zitat Bausewein C, Hau P, Borasio GDI, Voltz R (2003) How do patients with primary brain tumours die? Palliat Med 17:558–559PubMedCrossRef Bausewein C, Hau P, Borasio GDI, Voltz R (2003) How do patients with primary brain tumours die? Palliat Med 17:558–559PubMedCrossRef
16.
Zurück zum Zitat Faithfull S, Cook K, Lucas C (2005) Palliative care of patients with a primary malignant brain tumour: case review of service use and support provided. Palliat Med 19:545–550PubMedCrossRef Faithfull S, Cook K, Lucas C (2005) Palliative care of patients with a primary malignant brain tumour: case review of service use and support provided. Palliat Med 19:545–550PubMedCrossRef
17.
Zurück zum Zitat Gofton TE, Graber J, Carver A (2012) Identifying the palliative care needs of patients living with cerebral tumors and metastases: a retrospective analysis. J Neuro oncol 108:527–534CrossRef Gofton TE, Graber J, Carver A (2012) Identifying the palliative care needs of patients living with cerebral tumors and metastases: a retrospective analysis. J Neuro oncol 108:527–534CrossRef
18.
Zurück zum Zitat Stewart-Amidei C (2005) Managing symptoms and side effects during brain tumor illness. Expert Rev Neurother 5:71–76CrossRef Stewart-Amidei C (2005) Managing symptoms and side effects during brain tumor illness. Expert Rev Neurother 5:71–76CrossRef
19.
Zurück zum Zitat Ryan R, Booth S, Price S (2012) Corticosteroid-use in primary and secondary brain tumour patients: a review. J Neuro oncol 106:449–459CrossRef Ryan R, Booth S, Price S (2012) Corticosteroid-use in primary and secondary brain tumour patients: a review. J Neuro oncol 106:449–459CrossRef
20.
Zurück zum Zitat Anderson GD, Saneto RP (2012) Current oral and non-oral routes of antiepileptic drug delivery. Adv Drug Deliv Rev 64:911–918PubMedCrossRef Anderson GD, Saneto RP (2012) Current oral and non-oral routes of antiepileptic drug delivery. Adv Drug Deliv Rev 64:911–918PubMedCrossRef
21.
Zurück zum Zitat Armstrong T, Hancock C, Gilbert M (2000) Symptom management of the patient with a brain tumor at the end of life. Oncol Nurs Forum 27:616PubMed Armstrong T, Hancock C, Gilbert M (2000) Symptom management of the patient with a brain tumor at the end of life. Oncol Nurs Forum 27:616PubMed
22.
Zurück zum Zitat Nakken KO, Lossius MI (2011) Buccal midazolam or rectal diazepam for treatment of residential adult patients with serial seizures or status epilepticus. Acta Neurol Scand 124:99–103PubMedCrossRef Nakken KO, Lossius MI (2011) Buccal midazolam or rectal diazepam for treatment of residential adult patients with serial seizures or status epilepticus. Acta Neurol Scand 124:99–103PubMedCrossRef
23.
Zurück zum Zitat Cohen MZ, Torres-Vigil I, Burbach BE, de la Rosa A, Bruera E (2012) The meaning of parenteral hydration to family caregivers and patients with advanced cancer receiving hospice care. J Pain Symptom Manag 43:855–865CrossRef Cohen MZ, Torres-Vigil I, Burbach BE, de la Rosa A, Bruera E (2012) The meaning of parenteral hydration to family caregivers and patients with advanced cancer receiving hospice care. J Pain Symptom Manag 43:855–865CrossRef
24.
Zurück zum Zitat Lo B, Rubenfeld G (2005) Palliative sedation in dying patients: “we turn to it when everything else hasn’t worked”. JAMA 294:1810–1816PubMedCrossRef Lo B, Rubenfeld G (2005) Palliative sedation in dying patients: “we turn to it when everything else hasn’t worked”. JAMA 294:1810–1816PubMedCrossRef
25.
Zurück zum Zitat Earle CC, Ayanian JZ (2006) Looking back from death: the value of retrospective studies of end-of-life care. J Clin Oncol 24:838–840PubMedCrossRef Earle CC, Ayanian JZ (2006) Looking back from death: the value of retrospective studies of end-of-life care. J Clin Oncol 24:838–840PubMedCrossRef
26.
Zurück zum Zitat Oberndorfer S, Lahrmann H (2006) Supportive care and palliation in patients with malignant gliomas. Wien Med Wochenschr 156:364–368PubMedCrossRef Oberndorfer S, Lahrmann H (2006) Supportive care and palliation in patients with malignant gliomas. Wien Med Wochenschr 156:364–368PubMedCrossRef
27.
Zurück zum Zitat Teunissen SC, Wesker W, Kruitwagen C, de Haes HC, Voest EE, de Graeff A (2007) Symptom prevalence in patients with incurable cancer: a systematic review. J Pain Symptom Manag 34:94–104CrossRef Teunissen SC, Wesker W, Kruitwagen C, de Haes HC, Voest EE, de Graeff A (2007) Symptom prevalence in patients with incurable cancer: a systematic review. J Pain Symptom Manag 34:94–104CrossRef
28.
Zurück zum Zitat El-Jawahri A, Podgurski LM, Eichler AF, Plotkin SR, Temel JS, Mitchell SL, Chang Y, Barry MJ, Volandes AE (2010) Use of video to facilitate end-of-life discussions with patients with cancer: a randomized controlled trial. J Clin Oncol 28:305–310PubMedCentralPubMedCrossRef El-Jawahri A, Podgurski LM, Eichler AF, Plotkin SR, Temel JS, Mitchell SL, Chang Y, Barry MJ, Volandes AE (2010) Use of video to facilitate end-of-life discussions with patients with cancer: a randomized controlled trial. J Clin Oncol 28:305–310PubMedCentralPubMedCrossRef
29.
Zurück zum Zitat Von Roenn JH, von Gunten CF (2003) Setting goals to maintain hope. J Clin Oncol 21:570–574CrossRef Von Roenn JH, von Gunten CF (2003) Setting goals to maintain hope. J Clin Oncol 21:570–574CrossRef
30.
Zurück zum Zitat Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, Dahlin CM, Blinderman CD, Jacobsen J, Pirl WF, Billings JA, Lynch TJ (2010) Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 363:733–742PubMedCrossRef Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, Dahlin CM, Blinderman CD, Jacobsen J, Pirl WF, Billings JA, Lynch TJ (2010) Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 363:733–742PubMedCrossRef
31.
Zurück zum Zitat Yoong J, Park ER, Greer JA, Jackson VA, Gallagher ER, Pirl WF, Back AL, Temel JS (2013) Early palliative care in advanced lung cancer: a qualitative study. JAMA Intern Med 173:283–290PubMedCrossRef Yoong J, Park ER, Greer JA, Jackson VA, Gallagher ER, Pirl WF, Back AL, Temel JS (2013) Early palliative care in advanced lung cancer: a qualitative study. JAMA Intern Med 173:283–290PubMedCrossRef
32.
Zurück zum Zitat Detering KM, Hancock AD, Reade MC, Silvester W (2010) The impact of advance care planning on end of life care in elderly patients: randomised controlled trial. Br Med J 340:c1345CrossRef Detering KM, Hancock AD, Reade MC, Silvester W (2010) The impact of advance care planning on end of life care in elderly patients: randomised controlled trial. Br Med J 340:c1345CrossRef
33.
Zurück zum Zitat Sizoo EM, Taphoorn MJ, Uitdehaag B, Heimans JJ, Deliens L, Reijneveld JC, Pasman HR (2013) The end-of-life phase of high-grade glioma patients: dying with dignity? Oncologist 18:198–203PubMedCentralPubMedCrossRef Sizoo EM, Taphoorn MJ, Uitdehaag B, Heimans JJ, Deliens L, Reijneveld JC, Pasman HR (2013) The end-of-life phase of high-grade glioma patients: dying with dignity? Oncologist 18:198–203PubMedCentralPubMedCrossRef
34.
Zurück zum Zitat Sundararajan V, Bohensky MA, Moore G, Brand CA, Lethborg C, Gold M, Murphy MA, Collins A, Philip J (2014) Mapping the patterns of care, the receipt of palliative care and the site of death for patients with malignant glioma. J Neurooncol 116:119–126. doi:10.1007/s11060-013-1263-7 Sundararajan V, Bohensky MA, Moore G, Brand CA, Lethborg C, Gold M, Murphy MA, Collins A, Philip J (2014) Mapping the patterns of care, the receipt of palliative care and the site of death for patients with malignant glioma. J Neurooncol 116:119–126. doi:10.​1007/​s11060-013-1263-7
35.
Zurück zum Zitat Sizoo EM, Pasman HRW, Buttolo J, Heimans JJ, Klein M, Deliens L, Reijneveld JC, Taphoorn MJB (2012) Decision-making in the end-of-life phase of high-grade glioma patients. Eur J Cancer 48:226–232PubMedCrossRef Sizoo EM, Pasman HRW, Buttolo J, Heimans JJ, Klein M, Deliens L, Reijneveld JC, Taphoorn MJB (2012) Decision-making in the end-of-life phase of high-grade glioma patients. Eur J Cancer 48:226–232PubMedCrossRef
Metadaten
Titel
End-of-life symptoms and care in patients with primary malignant brain tumors: a systematic literature review
verfasst von
Tobias Walbert
Muhib Khan
Publikationsdatum
01.04.2014
Verlag
Springer US
Erschienen in
Journal of Neuro-Oncology / Ausgabe 2/2014
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-014-1393-6

Weitere Artikel der Ausgabe 2/2014

Journal of Neuro-Oncology 2/2014 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Demenzkranke durch Antipsychotika vielfach gefährdet

Demenz Nachrichten

Der Einsatz von Antipsychotika gegen psychische und Verhaltenssymptome in Zusammenhang mit Demenzerkrankungen erfordert eine sorgfältige Nutzen-Risiken-Abwägung. Neuen Erkenntnissen zufolge sind auf der Risikoseite weitere schwerwiegende Ereignisse zu berücksichtigen.

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

29.05.2024 Hyponatriämie Nachrichten

Eine ältere Frau trinkt regelmäßig Sennesblättertee gegen ihre Verstopfung. Der scheint plötzlich gut zu wirken. Auf Durchfall und Erbrechen folgt allerdings eine Hyponatriämie. Nach deren Korrektur kommt es plötzlich zu progredienten Kognitions- und Verhaltensstörungen.

Schutz der Synapsen bei Alzheimer

29.05.2024 Morbus Alzheimer Nachrichten

Mit einem Neurotrophin-Rezeptor-Modulator lässt sich möglicherweise eine bestehende Alzheimerdemenz etwas abschwächen: Erste Phase-2-Daten deuten auf einen verbesserten Synapsenschutz.

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.